glp 1 for alcoholism Frontiers GLP-1 Medications and Alcohol: A

Theres a link between your weight and your risk of sleep apnea

JAMA Network Open, 7(1), e2350408

[DOI] [PMC free article] [PubMed] [Google Scholar] 197.Holt R.I., et al

Depending on the medication and the patient population, research and approvals have supported benefits in areas like: Cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity (for specific products) Kidney protection in people with type 2 diabetes and chronic kidney disease (semaglutide showed benefit in a large kidney outcomes trial) Obstructive sleep apnea in adults with obesity (tirzepatide has an FDA-approved indication for moderate to severe OSA in this population) Fatty liver disease and MASH (semaglutide has shown promising results in phase 3 research) Addiction to opioids and alcohol This is why these medications are now part of bigger medical conversations: heart, kidney, liver, sleep health and substance abuse

Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes

Marketed under the brand name Wegovy, the tablet is authorized for chronic weight management in adults with obesity or who are overweight and also have at least one related health condition